Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy GlaxoSmithKline stock (GSK)

Buy GlaxoSmithKline stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

GlaxoSmithKline is a drug manufacturers - general business based in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $33.58 – a decrease of 4.63% over the previous week. GlaxoSmithKline employs 70,212 staff and has a trailing 12-month revenue of around $31.3 billion.

Our top picks for where to buy GlaxoSmithKline PLC ADR stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy GlaxoSmithKline stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – GSK. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy GlaxoSmithKline stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

GlaxoSmithKline stock price (NYSE: GSK)

Use our graph to track the performance of GSK stocks over time.

GlaxoSmithKline shares at a glance

Information last updated 2024-12-12.
Latest market close$33.58
52-week range$32.83 - $44.85
50-day moving average $36.58
200-day moving average $40.39
Wall St. target price$45.07
PE ratio 22.2258
Dividend yield $0.61 (4.54%)
Earnings per share (TTM) $1.55

Is it a good time to buy GlaxoSmithKline stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GlaxoSmithKline price performance over time

Historical closes compared with the close of $33.95 from 2024-12-13

1 week (2024-12-10) -3.58%
1 month (2024-11-15) 1.80%
3 months (2024-09-17) -20.23%
6 months (2024-06-17) -16.50%
1 year (2023-12-15) -5.38%
2 years (2022-12-16) 5.04%
3 years (2021-12-17) 38.859
5 years (2019-12-17) 37.9032

Is GlaxoSmithKline stock undervalued or overvalued?

Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GlaxoSmithKline's P/E ratio

GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, GlaxoSmithKline shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

GlaxoSmithKline's PEG ratio

GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7643. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

GlaxoSmithKline's EBITDA

GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.3 billion.

The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.

GlaxoSmithKline financials

Revenue TTM $31.3 billion
Operating margin TTM 8.33%
Gross profit TTM $19.9 billion
Return on assets TTM 7.24%
Return on equity TTM 21.85%
Profit margin 8.02%
Book value $3.43
Market Capitalization $71.4 billion

TTM: trailing 12 months

GlaxoSmithKline share dividends

37%

Dividend payout ratio: 37.41% of net profits

Recently GlaxoSmithKline has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.61 per share.

While GlaxoSmithKline's payout ratio might seem fairly standard, it's worth remembering that GlaxoSmithKline may be investing much of the rest of its net profits in future growth.

GlaxoSmithKline's most recent dividend payout was on 8 January 2025. The latest dividend was paid out to all shareholders who bought their shares by 14 November 2024 (the "ex-dividend date").

Have GlaxoSmithKline's shares ever split?

GlaxoSmithKline's shares were split on a 1226:1000 basis on 21 July 2022 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1226 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 18.4% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.

GlaxoSmithKline share price volatility

Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $32.825 up to $44.8549. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.33. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).

GlaxoSmithKline overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Frequently asked questions

What percentage of GlaxoSmithKline is owned by insiders or institutions?
Currently 0.056% of GlaxoSmithKline shares are held by insiders and 15.393% by institutions.
How many people work for GlaxoSmithKline?
Latest data suggests 70,212 work at GlaxoSmithKline.
When does the fiscal year end for GlaxoSmithKline?
GlaxoSmithKline's fiscal year ends in December.
Where is GlaxoSmithKline based?
GlaxoSmithKline's address is: 980 Great West Road, Brentford, United Kingdom, TW8 9GS
What is GlaxoSmithKline's ISIN number?
GlaxoSmithKline's international securities identification number is: US37733W2044
What is GlaxoSmithKline's CUSIP number?
GlaxoSmithKline's Committee on Uniform Securities Identification Procedures number is: 37733W105

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site